

0040-4039(95)00213-8

Isolation and Structure of Flutimide, a Novel Endonuclease Inhibitor of Influenza Virus

Otto D. Hensens*, Michael A. Goetz, Jerrold M. Liesch, Deborah L. Zink, Susan L. Raghoobar, Gregory L. Helms, and Sheo B. Singh

Merck Research Laboratories, P. O. Box 2000, Rahway, NJ 07065-0900 (USA)

Keywords: Flutranscription endonuclease inhibitor, 2D NMR, HMBC, SIMBA, EI-MS, FAB-MS, CI-MS

Abstract: The isolation and structure elucidation of flutimide (1), an inhibitor of flutranscription endonuclease from Delitschia confertaspora, a new species, is reported. The novel natural product is characterized by N-hydroxyimide and exocyclic enamine functionalities.

Influenza, an acute contagious respiratory disease is caused by influenza viruses A and B. The distinguishing characteristics of influenza are the mortality that can result from pulmonary infection which periodically causes epidemics. Influenza virus is a negative strand RNA virus with a segmented genome. Its mRNA synthesis is catalyzed by a virally-encoded transcription complex. This virus uniquely utilizes capped and methylated (cap 1) primers for its mRNA synthesis. Endonuclease, a unique enzyme that cleaves the capped cellular transcripts for further RNA elongation is critical for viral replication.¹ Thus inhibition of this enzyme could be potentially useful as a therapeutic target towards development of an anti-influenza drug.²



The novel natural product flutimide (1) was isolated from *Delitschia confertaspora*, a new species,³ collected from dung of a dassie in Namibia, using a Flu transcription biological screen.⁴ It selectively inhibits endonuclease and shows antiviral activity in cell culture. The titer of flutimide in the fermentation broth was very low and very difficult to improve.⁴ Only ~1 mg of material was initially available for structure determination which did not allow a clear distinction between 1 and the isomeric hydroxamic acid structure 2 to be made based on NMR and MS evidence alone. This was resolved in favor of 1 by synthetic and degradative studies when more of 1 became available. We report here on the isolation and structural studies of flutimide, corroboration of which was obtained by an unambiguous synthesis from L-leucine.⁵

Extraction of flutimide from fermentations was accomplished by treating broths with either ethyl acetate or methyl ethyl ketone, on the condition of operating at pH 2-2.5 (acidification with conc. H3PO4) rather than at the original pH (usually 6.5). Concentration of the extract was followed by a gel filtration step on Sephadex LH-20 in methanol and silica gel column chromatography on EM silica (methylene chloride to methanol gradient). Final purification was achieved by HPLC on a Whatman Partisil-5 ODS-3 column operated at room temperature and eluted with a gradient of acetonitrile in 0.1% TFA. In larger scale preparations, difficulties encountered in dealing with whole-broth extracts were avoided by simply first filtering the fermentation; the de-watered mycelial cake was stirred briefly with ethyl acetate to remove large amounts of non-polar impurities, then extracted with a 1:1 mixture of MEK and 0.01M H3PO4. The organic phase was pooled with the broth filtrate extract prior to the gel filtration step.

¹³C NMR data of flutimide [FTIR (ZnSe): 3241 (br), 1674, 1626, 1467, 1237, 937 cm-1; UV λ_{max} (MeOH) : 270, 360 (sh) nm] in CD₂Cl₂ at 125 MHz, indicated 12 carbons and 17 carbon-bound protons in agreement with the HR-EIMS derived empirical formula C₁₂H₁₈N₂O₃ (found m/z 238.1316, calculated 238.1317) assuming one active proton. This was supported by the formation of a mono-TMS derivative. COSY and ¹H NMR decoupling studies at 500 MHz indicated the presence of isobutyl and isobutylidene groups which could be elaborated to partial fragments **A** and **B** using the ¹H detected long-range ¹H-¹³C HMBC experiment optimized for 10 Hz. By EI-MS, fragment ions were observed at m/z 221.1290 (C₁₂H₁₇N₂O₂, calc 221.1290) and m/z 195.0770 (C9H₁₁N₂O₃, calc 195.0770), corresponding to losses of OH and the sidechain (C₃H₇) respectively. The [M-OH]⁺ loss was confirmed by spiking the sample with CD₃OD whereupon the [M-OD]⁺ fragment was observed from the deuterated molecular ion at m/z 239. This is consistent with the presence of an N-OH functionality in flutimide which was confirmed by a ²H-isotope ¹³C induced shift experiment by comparing spectra in CD₃OD and CD₃OH. No difference in ¹³C shifts were observed larger than 0.01 ppm ruling out an OH or NH group bound to carbon.



i, NaHCO₃, EtOH, reflux, then Ac₂O, 130⁰C; ii, t-BuOK, DMF-t-BuOH, Me₂CHCHO; iii, NH₂NH₂.H₂O; iv, HMDS, trace of TMSCI, reflux; v, MoO₅.Py.HMPA; vi, H₂, Pd/C Based on these data the N-hydroxyimide (1) and hydroxamic acid structures (2) were advanced. The Z configuration of the exocyclic double bond followed from a 1D HMBC (SIMBA)⁶ experiment. Selective irradiation of the carbon at 158.7 ppm gave a doublet of doublets for the ¹H resonance at $\delta 7.20$ [³*J*_{HH} = 10.1 Hz; ³*J*_{CH} = 3.3 Hz] where the small ³*J*_{CH} is consistent with a *syn* relationship between the vinylic proton and the carbonyl group.⁷ We initially favored 2 based on ¹H chemical shift arguments and on our inability to prepare the TMS derivative of the original small sample. Synthetic studies were therefore initiated as outlined in Scheme 1 which yielded the *E* and *Z* isomeric structures of **8** as intermediates (only the major *E* isomer is shown for structures **5-8**).⁸ These were expected to produce the same hydrogenation product as would have been expected for **2**. Actual hydrogenation of **8** with Pd/C was accompanied with reductive cleavage of the N-OH group to give a 95:5 mixture of **9** and **10**^{11,12}, different from the symmetrical, *des* N-hydroxy product **11**¹³ obtained under identical conditions from **1** (Scheme 2). The CI mass spectrum of compound **11** gave a parent ion at m/z



227 (M+H). A facile elimination of CO was observed by both CIMS and EIMS to give an ion at m/z 199 (M-CO+H) and 197 (M-CO-H) respectively. This type of facile loss of CO was not observed in spectra of **9** and **10**. The most critical EI-MS fragment of **11** was observed at m/z 154.1603 $[C4H9CH=N=CHC4H9]^+$ as shown, which clearly supports the imide structure. More significantly, acid hydrolysis of **11** yielded the dicarboxylic acid **12** which was characterized by GC-MS analysis as a TMS derivative. Proto- and perdeutero-TMS derivatives were prepared separately to allow determination of the number of TMS groups present in observed ions. The di-TMS derivative of **12** was observed and it exhibited typical TMS-amino acid fragment ions¹⁴ at m/z 374 (di-TMS M⁺ - Me), 346 (374 - CO), and 272 (di-TMS M⁺ - CO₂Si(CH₃)₃). On the other hand **9** and **10** gave only leucine as expected (observed m/z 275 (di-TMS M⁺), 260 (di-TMS M⁺ - Me), and 158 (di-TMS M⁺ - CO₂Si(CH₃)₃). The structure of flutimide was therefore assigned as **1**.

Flutimide is the first natural product shown to inhibit the cap-dependent endonuclease of influenza virus. Previously,² a series of 4-substituted 2,4-dioxobutanoic acids were found to inhibit the endonuclease exhibiting IC₅₀s in the range 0.2 to 29.0 uM compared to a value of \sim 3µM for flutimide.⁴

References and Notes

- 1. Plotch, S. J.; Bouloy, M.; Ulmanen, I.; Krug, R. M. Cell 1981, 23, 847-858.
- Tomassini J.; Davies, M. E.; Armstron, M. E.; Hastings, J.; Hazuda, D.; Lewis, J.; McClements, W.; Wolfe, A.; Selnick, H.; Baldwin, J.; Bourgeois, M.; Ponticello, G.; Raszilowski, E.; Smith, G.; Tebben, A. Antimicrob. Agents Chemother. 1994,38, 2827.
- 3. Pelaez, F.; Polishook, J. D.; Valldosera, M.; Guarro, J. Mycotaxon 1994, 50, 115-122.

- 4. Tomassini J.; Lingham, R.B.; et al. submitted to Antimicrob. Agents Chemother.
- 5. Singh, S. B. accompanying paper.
- 6. Crouch, R.C.; Martin, G. E. J. Magn. Reson. 1991, 92, 189-194.
- 7. Vogeli, U.; Von Philipsborn, W. Org. Magn. Reson. 1975, 7, 617-627.
- 8. Scheme 1: Fischer esterification of Gly-L-Leu gave **3** which on refluxing in NaHCO₃/EtOH and acetylation gave **4**. Aldol condensation with isobutyraldehyde gave a 7:3 mixture of Z and E isomers **5** (CI-MS m/z 267 [M+H]⁺) in >70% yield which were differentiated by NOE measurements. The marked difference in olefinic and isopropyl CH chemical shifts in CDCl₃ [E, δ 5.58 (d, J = 9.9 Hz)/3.53m; Z, δ 6.15 (d, J = 10.2 Hz)/ 2.71m] has precedence.⁹ In this step aldol condensation is followed by acyl migration and base-mediated acetate elimination. After deacetylation to **6** (*E*/Z), silylation under reflux to **7** followed by careful removal of reagent and *in situ* oxidation with MoO₅.pyridine.HMPA (prepared fresh in three steps)¹⁰ gave **8** (*E*/Z) as well as aromatized product by elimination of water.
- 9. Robins, D. J.; Sefton, M. A. Phytochemistry 1984, 23, 200-201.
- 10. Rigby, J. H.; Qabar, M. J. Org. Chem. 1989, 54, 5852-5853.
- 11. **9**: Colorless oil: CIMS: m/z 227 [M+H]⁺; ¹H NMR (CD₃OD, 400 MHz): δ0.95 (3H, d, J = 6.8 Hz), 0.97 (3H, d, J = 6.8 Hz), 1.61 (1H, ddd, J = 5.6, 8.8, 14.0 Hz), 1.72 (1H, ddd, J = 4.8, 8.4, 13.6 Hz), 1.84 (1H, m), 3.90 (1H, dd, J = 4.8, 8.8 Hz); ¹³C NMR (CD₃OD, 100 MHz): 22.1 (2 x Me), 23.6 (2 x Me), 25.5 (2 x CH), 45.9 (2 x CH₂), 54.9 (2 x CH), 171.3 (2 x CON) ppm. The major product **9** is symmetrical judging from its ¹H and ¹³C NMR spectra. It was therefore assigned the *S*,*S* diastereomer consistent with previous work on the asymmetric reduction of α,β-dehydroamino acid residues in cyclodipeptides.¹²
- 12. Kanmera, T.; Lee, S.; Aoyagi, H.; Izumiya, N. Int. J. Peptide Protein Res. 1980, 16, 280-290.
- 13. 11: Colorless oil; FTIR (ZnSe): 3299 (br), 1743 (sh), 1690, 1467, 1204 cm-1; ¹H NMR (CD₃OD, 400 MHz): δ0.94 (2 x 3H, d, J = 6.4 Hz), 0.97 (2 x 3H, d, J = 6.4 Hz), 1.87-1.98 (2 x 3H, m), 3.61 (2 x 1H, dd, J = 4.0, 9.6 Hz); ¹³C NMR (CD₃OD, 100 MHz): 21.9 (2 x Me), 23.6 (2 x Me), 26.0 (2 x CH), 41.0 (2 x CH2), 58.8 (2 x CH), 173.6 (2 x CON) ppm.
- 14. Leimer, K.; Rice, R.; Gehrke, C. J. Chromatogr. 1977, 141, 355-375.

(Received in USA 7 December 1994; revised 24 January 1995; accepted 26 January 1995)